Internet Archive Scholar

Understanding the treatment algorithm of patients with metastatic pancreatic neuroendocrine neoplasms: A single-institution retrospective analysis comparing outcomes of chemotherapy, molecular targeted therapy and peptide receptor radionuclide therapy in 255 patients

Aimee R Hayes, Ingrid Y F Mak, Nicholas Evans, Rishi Naik, Alexander Crawford, Bernard Khoo, Ashley B Grossman, Shaunak Navalkissoor, Jennifer Watkins, Tu Vinh Luong, Dalvinder Mandair, Christos Toumpanakis (+3 others)
2020 Neuroendocrinology  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (988.7 kB)
https://web.archive.org/web/20211202072300/https://discovery.ucl.ac.uk/id/eprint/10112272/1/511662.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

The number of therapeutic options for patients with pancreatic neuroendocrine neoplasms (PNEN) has increased, but the optimal therapeutic algorithm has not been defined due to lack of randomised trials comparing different modalities. Methods We performed a retrospective study in patients with metastatic PNEN treated with ≥1 line of systemic therapy. The relationship between baseline characteristics, treatment type and time to treatment failure (TTF), time to progression (TTP) and overall
more » ... l (OS) was analysed using the Kaplan-Meier method. Univariate and multivariate analyses were performed using the Cox proportional hazards model. Results Two hundred and fifty-five patients with metastatic PNEN had 491 evaluable lines of therapy. Independent predictors of TTF included treatment type, Ki-67, tumour grade and chromogranin A. To reduce selection bias, a subgroup of 114 patients with grade 2 (G2) metastatic pancreatic neuroendocrine tumours (PNET) was analysed separately. These patients had received 234 lines of treatment (105 chemotherapy, 82 molecular targeted therapy, and 47 peptide receptor radionuclide therapy [PRRT]). In the G2 cohort, TTF and TTP were superior for PRRT compared with both chemotherapy and molecular targeted therapy. OS in the G2 cohort was also superior for those that had received PRRT compared with those that had not (median 84 vs 56 months; HR 0.55, 95%CI 0.31-0.98, p=0.04). Conclusions This study suggests that PRRT is associated with superior clinical outcomes relative to other systemic therapies for G2 metastatic PNET. Prospective studies are required to confirm these observations. .
doi:10.1159/000511662 pmid:32950978 fatcat:ou5fo5wssraybiqbu2hsxqfgmm
Citation

Aimee R Hayes, Ingrid Y F Mak, Nicholas Evans, Rishi Naik, Alexander Crawford, Bernard Khoo, Ashley B Grossman, Shaunak Navalkissoor, Jennifer Watkins, Tu Vinh Luong, Dalvinder Mandair, Christos Toumpanakis, Christina Thirlwell, Martyn E Caplin, Tim Meyer. "Understanding the treatment algorithm of patients with metastatic pancreatic neuroendocrine neoplasms: A single-institution retrospective analysis comparing outcomes of chemotherapy, molecular targeted therapy and peptide receptor radionuclide therapy in 255 patients." Neuroendocrinology 111.9 (2020)